Stock News & Analysis

Palantir has been a big winner due to soaring demand for artificial intelligence, and Ives believes that will continue to be the case next year.

It would be the largest-ever merger in the restaurant sector, though it's still far from certain that it will happen.

Salesforce's 18% net margin and fortress balance sheet contrast sharply with ServiceNow's 21% revenue growth and AI-driven momentum, a classic growth-versus-value showdown.

Dividend stocks are getting hit by rising rates, but this trio of high-yielders is still worth buying and holding.

Both companies burn cash and carry heavy debt, but are chasing huge market potential for their services.

We'll know for sure in just a few days.

What's bad for bond investors doesn't have to be bad for stocks.

Eli Lilly isn't content with the success of its current GLP-1 drugs; it's on the hunt for even better weight loss solutions.

There's always more to the matter than mere yield (although dividend yields are still important).

This under-the-radar enterprise software stock boasts a Superscore of 83 from our Hidden Gems Primary database, part of The Motley Fool's Moneyball Database system. Here's why.

Chewy trades at a fraction of Coupang's valuation multiple, but one faces Amazon's shadow while the other grapples with regulatory headwinds and a major data breach.

SpaceX's recent Starship launch marked a milestone for the company, as it was its first one that successfully went into orbit.

Every investor should have exposure to energy, but with oil prices high, you need to be selective if you are looking for reliable dividends.

The front-runner of the nascent eVTOL industry could mint new millionaires.

The S&P 500 is trading at historical valuations, making some investors nervous a stock market crash is on the way.

Major index funds are heavily concentrated with the same few tech names. How can investors avoid overlapping stocks?

Amazon wants to acquire AI startup Decart, Nvidia to expand Reflection AI investment, and more…

Oppenheimer raised Viking Therapeutics' price target to $120, citing strong trial data, and an improving probability of success for its key drug.

What comes next for this memory hardware giant?

Independent estimates call for Social Security benefits to rise by 3.5% in 2027 -- but this isn’t the biggest story.